SLAMF6 anticorps (AA 248-331) (FITC)

N° du produit ABIN7169784

Détail du produit anti-SLAMF6 anticorps (FITC)

Antigène: SLAMF6 (SLAM Family Member 6 (SLAMF6))

Épitope: AA 248-331

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SLAMF6 est conjugé à/à la FITC

Application: Veuillez nous consulter SVP

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human SLAM family member 6 protein (248-331AA)

Isotype: IgG

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur SLAMF6

Antigène: SLAMF6 (SLAM Family Member 6 (SLAMF6))

Autre désignation: SLAMF6 (SLAMF6 Produits)

Synonymes: anticorps SLAMF6, anticorps CD352, anticorps KALI, anticorps KALIb, anticorps Ly108, anticorps NTB-A, anticorps NTBA, anticorps SF2000, anticorps KAL1, anticorps KAL1b, anticorps RGD1561848, anticorps SLAM family member 6, anticorps SLAMF6, anticorps Slamf6

Sujet:

Background: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Triggers cytolytic activity only in natural killer cells (NK) expressing high surface densities of natural cytotoxicity receptors (PubMed:11489943, PubMed:16920955). Positive signaling in NK cells implicates phosphorylation of VAV1. NK cell activation seems to depend on SH2D1B and not on SH2D1A (PubMed:16920955). In conjunction with SLAMF1 controls the transition between positive selection and the subsequent expansion and differentiation of the thymocytic natural killer T (NKT) cell lineage (By similarity). Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion, the costimulatory activity requires SH2D1A (PubMed:22184727, PubMed:16920955). Promotes recruitment of RORC to the IL-17 promoter (PubMed:22989874). In conjunction with SLAMF1 and CD84/SLAMF5 may be a negative regulator of the humoral immune response. In the absence of SH2D1A/SAP can transmit negative signals to CD4(+) T-cells and NKT cells. Negatively regulates germinal center formation by inhibiting T-cell:B-cell adhesion, the function probably implicates increased association with PTPN6/SHP-1 via ITSMs in absence of SH2D1A/SAP. However, reported to be involved in maintaining B-cell tolerance in germinal centers and in preventing autoimmunity (By similarity).

Aliases: Activating NK receptor antibody, CD352 antibody, KALI antibody, KALIb antibody, LY108 antibody, MGC104953 antibody, Natural killer T and B cell antigen antibody, NK T B antigen antibody, NK-, T-, and B-cell antigen antibody, NK-T-B-antigen antibody, NTB A antibody, NTB-A antibody, NTBA antibody, NTBA receptor antibody, SF2000 antibody, SLAF6_HUMAN antibody, SLAM family member 6 antibody, SLAM family member 6 precursor antibody, SLAM Family Receptor antibody, Slamf6 antibody

UniProt: Q96DU3